

References

1. Denisyuk VI, Ivanov VP. Logos,2001.206 p. (in Ukr)
2. Iskenderov BG, Rakhmatullof FK. *Rossiyskiy cardiologicheskiy journal – Rus J Cardiol* 2001;4:26–30. (in Russ)
3. Iskenderov BG, Lokhina TV, Liusov VA, Kapelovich TYu. *Rossiyskiy cardiologicheskiy journal – Rus J Cardiol* 2006;1:22–6.
4. Kovalenko BN. Morion,2008.1424 p. (in Ukr)
5. Kushakovskiy MS. Foliant,1994.176 p. (in Russ)
6. Serdechnaya EV, Tatarskiy BA, Kazakevich EV. *Clinicheskaya medicina – J Clin Med* 2009;3:35–7. (in Russ)
7. Solovyan AN. *Ukrainskiy cardiologicheskiy journal – Ukr J Cardiol* 2012; 3:55–62.
8. Chazova IE, Dmitriyev VV, Tolpigina SN, Ratova LG. *Terapevticesckiy arhiv – Ther Arch* 2002;9:50–6. (in Russ)
9. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohnloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. ESC Guidelines for the Management of Atrial Fibrillation (2010 Version). *Eur Heart J* 2010;6:1–61.
10. Ciaroni S, Cuenould L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. *Am Heart J* 2000;139:814–9.
11. Cohen A, Chauvel C. The best of 2001. Echocardiography. *Arch Mal Coeur Vaiss* 2002;95:21–8.
12. Daoud EG, Bogun F, Goyal R, Harvey M, Man KC, Strickberger SA, Moradi F. Effect on atrial fibrillation on atrial refractoriness in humans. *Circulation* 1996;94:1600–6.
13. Eijsbonts SC, Majidi M, van Sandvoort M, Allessie MA. Effects of acute atrial dilation on heterogeneity in conduction in the isolated rabbit heart. *J Cardiovasc Electrophysiol* 2003;14:269–76.
14. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary. *Eur Heart J* 2006;27:1979–2030.
15. Friedman H.S. Heart rate variability in atrial fibrillation related to left atrial size. *Am J Cardiol* 2004;93:705–9.
16. Gerds E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, Dahlof B, Devereux RB. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. *Hypertens* 2002;39:739–43.

17. Gottdiener JS, Kitzman DW, Aurigemma GP, Arnold AM, Manolio TA. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons \geq 65 years of ages / the cardiovascular health Study. *Am J Cardiol* 2006;97:83–9.
18. Heeringa J, van der Kuip DA, Hofman A, Kars JA, van Herhen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalance, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. *Eur Heart J* 2006;27:949–53.
19. Heist EK, Ruskin JN. Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. *Prog Cardivasc Dis* 2006;48:256–69.
20. Kaftan AH, Kaftan O. Q-T intervals and heart rate variability in hypertensive patients. *Jpn Heart J* 2000;41:73–82.
21. Levy S, Crijns HJ. Atrial Fibrillation Management: a prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. *Eur Heart J* 2005;26:2422–34.
22. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 2004;110:1042–6.
23. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Sevard JB, Bailey KR, Iwasaka T, Tsang TS. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community – based study. *Stroke* 2005;36:2362–2366.
24. Nattel S, Shiroshita-Takeshita A, Broundel BJ, Rivard L. Mechanisms of atrial fibrillation: lessons from animal models. *Progr Cardiovasc Dis* 2005;48:9–28.
25. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davis DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Levy S, Crijns HJ. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J* 2005;26:2422–34.
26. Oikarinen J, Neiminen MS, Vitasalo M. Relation of Q-T interval and Q-T dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE Study. The Losartan intervention For Endpoint Reduction. *Hypertension* 2001;19:883–91.
27. Schotten U, Verheule S, Kirchof P, Goette A. Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. *Physiol Rev* 2011;91:265–325.
28. Stollberger C, Finsterer J, Ernst G, Schneider BZ. Is left atrial appendage occlusion usefull for prevention of stroke or embolism in atrial fibrillation ? *Kardiol* 2002;91:376–9.
29. Thrall G, Lane D, Carrol D, Lip GYH. Quality of life in patients with atrial fibrillation: a systematic review. *Am J Med* 2006;119:448e1–e19.
30. Tomita T, Takei M, Saikawa Y, Hanaoka T, Uchikawa S, Tsutsui H, Aruga M, Miyashita T, Yazaki Y, Imamura H, Kinoshita O, Owa M, Kubo K. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. *Clin Cardiol* 2003;26:341–7.

31. Verdecchia P, Reboldi G, Gattobigio R, Rentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati S. Atrial fibrillation in hypertension: predictors and outcome. *Hypertens* 2003;41:218–23.